Search

Author/Creator Fogdell-Hahn, A.

1. 10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals. Issue 1 (1st January 2020)

Authors:
Tourdot, S.; Abdolzade-Bavil, A.; Bessa, J.; Broët, P.; Fogdell-Hahn, A.; Giorgi, M.; Jawa, V.; Kuranda, K.; Legrand, N.; Pattijn, S.; Pedras-Vasconcelos, J. A.; Rudy, A.; Salmikangas, P.; Scott, D. W.; Snoeck, V.; Smith, N.; Spindeldreher, S.; Kramer, D.
Journal:
MAbs
Issue:
Volume 12:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. AB0310 TROUGH CONCENTRATION AND ESTIMATED CLEARANCE CAN DETECT IMMUNOGENICITY TO ADALIMUMAB IN RA PATIENTS: A PROSPECTIVE LONGITUDINAL MULTICENTRE STUDY. (2nd June 2020)

Authors:
Ternant, D.; Elhasnaoui, J.; Szely, N.; Hacein-Bey, S.; Gleizes, A.; Richez, C.; Manson, J.; Soubrier, M.; Brocq, O.; Avouac, J.; Fogdell-Hahn, A.; Dönnes, P.; Paintaud, G.; Desvignes, C.; Deisenhammer, F.; Spindeldreher, S.; Pallardy, M.; Mariette, X.; Mulleman, D.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
1453
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. OP0232 Female gender and positive rheumatoid factor predict low serum infliximab levels and positive anti-drug antibodies, which associate with treatment failure on infliximab in patients with early rheumatoid arthritis. report from the swefot trial population. (12th June 2018)

Authors:
Hambardzumyan, K.; Hermanrud, C.; Marits, P.; Vivar, N.; Ernestam, S.; Wallman, J.K.; van Vollenhoven, R.F.; Fogdell-Hahn, A.; Saevarsdottir, S.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77(2018)Supplement 2
Page Start:
165
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗